Viewing Study NCT00320255



Ignite Creation Date: 2024-05-05 @ 4:51 PM
Last Modification Date: 2024-10-26 @ 9:24 AM
Study NCT ID: NCT00320255
Status: COMPLETED
Last Update Posted: 2016-08-16
First Post: 2006-04-28

Brief Title: A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced Metastatic Cancer
Sponsor: Bristol-Myers Squibb
Organization: Bristol-Myers Squibb

Study Overview

Official Title: A Randomized Double-blind Placebo-controlled Study of Apixaban for the Prevention of Thromboembolic Events in Patients Undergoing Treatment for Advanced Cancer A Phase 2 Pilot Study
Status: COMPLETED
Status Verified Date: 2016-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to learn whether apixaban is well-tolerated and acceptable as anticoagulant therapy when administered to patients with advanced or metastatic cancer and at increased risk for venous thromboembolic events Demonstration of a favorable benefitrisk profile could lead to significant reduction in this serious and sometimes fatal complication of ongoing cancer and its treatment
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None